JAKARTA - The Ministry of Industry is increasingly focused on developing the pharmaceutical industry in the country so that it can create an independent and competitive sector. Moreover, Indonesia is supported by the potential of the availability of abundant natural resources that can be used as raw materials.
"Indonesia has the best biodiversity in the world such as ginger, lempuyang, nutmeg, patchouli and others, which of course can be the main capital in building self-reliance to produce drugs," said the Head of the Industrial Research and Development Agency (BPPI) of the Ministry of Industry, Doddy Rahadi at Jakarta, Wednesday (14/10).
The Head of BPPI said that his party is encouraging the development of traditional medicines into modern Indonesian native medicines (OMAI) in the form of Standardized Herbal Medicines (OHT) and Fitofarmaka. In order to achieve this goal, a number of work units under BPPI are encouraged to increase R&D activities in order to produce the needed innovations.
Currently, BBKK Jakarta is in the process of designing a House of Wellness facility which will be equipped with a mini plant certified for Good Traditional Medicine Manufacturing Method (CPOTB), Smart Laboratory (R&D and QC), Center of Essential Oils (Learning Factory and Laboratory of Essential Oils Authentication) ) and soft computing room. "This program is included in the BBKK phytopharmaca development roadmap 2021-2026," said Doddy.
In 2021, it is planned to construct building infrastructure and support it, following the CPOTB standard. Continued in 2022, building equipment installations and CPOTB certification. It is hoped that OHT can be produced in 2024, and by 2026 the facilities will be able to produce phyto-pharmacy. (LM)